Baxter International Inc.
24.39USD
-0.4700 (-1.89%)
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $0.52▼ | $0.53 | 2 | 7 |
| Next quarter | $0.61▼ | $0.66 | 1 | 8 |
| Current year | $2.05▲ | $1.92 | 12 | 0 |
| Next year | $2.04▲ | $2.01 | 11 | 1 |
Beat in 3 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $0.37 | $0.56 | +0.19 (+52.5%) |
| 2026-03-31 | $0.31 | $0.36 | +0.05 (+15.9%) |
| 2025-12-31 | $0.54 | $0.44 | -0.10 (-17.8%) |
| 2025-09-30 | $0.6 | $0.69 | +0.09 (+15.4%) |
264 ratings from 30 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| TD Cowen | Maintained | Hold | $24 $29 | Jul 31, 2026 |
| Wells Fargo | Maintained | Equal-Weight | $19 $23 | Jul 31, 2026 |
| Stifel | Maintained | Hold | $24 $28 | Jul 31, 2026 |
| Citigroup | Upgraded from Sell | Neutral | $17 $28 | Jul 31, 2026 |
| UBS | Maintained | Neutral | $19 $25 | Jul 28, 2026 |
| Stifel | Maintained | Hold | $19 $24 | Jul 28, 2026 |
| TD Cowen | Maintained | Hold | $20 $24 | Jul 27, 2026 |
| Goldman Sachs | Maintained | Neutral | $19 $21 | Jul 15, 2026 |
| Evercore ISI Group | Maintained | Outperform | $22 $24 | Jul 6, 2026 |
| Citigroup | Downgraded from Neutral | Sell | $19 $17 | May 28, 2026 |
| Barclays | Maintained | Overweight | $25 $27 | May 4, 2026 |
| Evercore ISI Group | Maintained | Outperform | $23 $22 | Apr 6, 2026 |
| Citigroup | Maintained | Neutral | $21 $19 | Mar 11, 2026 |
| Goldman Sachs | Maintained | Neutral | $21 $17 | Feb 17, 2026 |
| Barclays | Maintained | Overweight | $30 $25 | Feb 13, 2026 |
| Barclays | Maintained | Overweight | $36 $30 | Jan 9, 2026 |
| Morgan Stanley | Maintained | Underweight | $19 $15 | Dec 2, 2025 |
| Citigroup | Maintained | Neutral | $26 $21 | Oct 31, 2025 |
| Goldman Sachs | Maintained | Neutral | $25 $22 | Oct 31, 2025 |
| UBS | Maintained | Neutral | $24 $21 | Oct 31, 2025 |
| Argus Research | Downgraded from Buy | Hold | — | Oct 31, 2025 |
| Evercore ISI Group | Maintained | Outperform | $33 $31 | Oct 7, 2025 |
| Barclays | Maintained | Overweight | $41 $36 | Aug 4, 2025 |
| Stifel | Downgraded from Buy | Hold | $36 $25 | Aug 4, 2025 |
| UBS | Maintained | Neutral | $35 $24 | Aug 4, 2025 |
44 filings from 26 insiders · 0 buy / 0 sell over 6m
Officers and directors of BAX, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Hider Andrew P.Director; Officer, President and CEO | Tax | 54.3k | $25.70 | $1.39M | Sep 2, 2026 |
| Foster JulieOfficer, President, Front Line Care | Tax | 2.1k | $25.70 | $54k | Sep 2, 2026 |
| Teaff JamesOfficer, President, CCS | Tax | 750 | $25.48 | $19k | Sep 1, 2026 |
| ZIELINSKI ANITA A.Chief Financial Officer | Grant | 13.4k | — | — | Jun 1, 2026 |
| AMPOFO WILLIAM A. IIDirector | Grant | 12.8k | — | — | May 5, 2026 |
| WENDELL AMY MCBRIDEDirector | Grant | 12.8k | — | — | May 5, 2026 |
| SHAFER DAVID BRENTChairman of the Board | Grant | 12.8k | — | — | May 5, 2026 |
| MCDONNELL MICHAEL RDirector | Grant | 12.8k | — | — | May 5, 2026 |
| WILKES DAVID S. M.D.Director | Grant | 12.8k | — | — | May 5, 2026 |
| SCHLICHTING NANCY MDirector | Grant | 12.8k | — | — | May 5, 2026 |
| CRAIG JEFFREY ADirector | Grant | 12.8k | — | — | May 5, 2026 |
| MORRISON PATRICIA BDirector | Grant | 12.8k | — | — | May 5, 2026 |
| ZIELINSKI ANITA A.Officer | Grant | 30.9k | — | — | Feb 27, 2026 |
| ROSENBLOOM DAVID SGeneral Counsel | Grant | 26.7k | — | — | Feb 27, 2026 |
| HIDER ANDREW PChief Executive Officer | Grant | 201.8k | — | — | Feb 27, 2026 |
| CARLISLE CYNTHIAOfficer | Grant | 29.7k | — | — | Feb 27, 2026 |
| SORIANO MARIA CECILIAOfficer | Grant | 23.7k | — | — | Feb 27, 2026 |
| GRADE JOEL T.Chief Financial Officer | Grant | 42.7k | — | — | Feb 27, 2026 |
| MCDONNELL MICHAEL RDirector | Grant | 1.8k | — | — | Feb 13, 2026 |
| ROSENBLOOM DAVID SGeneral Counsel | Grant | 17.1k | — | — | Feb 9, 2026 |
No analyst notes on BAX yet.
Analyst Ratings
11 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 1 | 1 | 11 | 0 | 0 | Hold2.77 |
| 1 mo ago | 1 | 1 | 12 | 0 | 0 | Hold2.79 |
| 2 mo ago | 0 | 2 | 11 | 1 | 0 | Hold2.93 |